NEFL and Parkinson disease: Our primary focus was the use of NfL in the discrimination of individuals with MSA from the healthy control group (HC), patients with Parkinson’s disease (PD) and Lewy body dementia (LBD: PD dementia plus dementia with Lewy bodies—DLB).